Blog

Elvina Almuradova: Promising results with Daraxonrasib in RAS-mutant PDAC

Elvina Almuradova/LinkedIn

Jan 28, 2025, 08:26

Elvina Almuradova: Promising results with Daraxonrasib in RAS-mutant PDAC

Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, posted the following on LinkedIn:

“Daraxonrasib (RMC-6236), an investigational pan-RAS inhibitor, shows promising early results in RAS-mutant PDAC, with a 36% response rate in second-line therapy and a median overall survival of 14.5 months. Common toxicities include rash, diarrhea, and nausea, but they are mostly manageable. The phase 3 RASolute trial is ongoing to compare it with standard chemotherapy.

I’m thrilled to have had the opportunity to join the phase 1 trial of this groundbreaking drug at IEO Istituto Europeo di Oncologia.”

cancer chemotherapy alternatives clinical trials DaraxONRASib Elvina Almuradova IEO Istituto Europeo di Oncologia OncoDaily Oncology oncology research Pancreatic Cancer RAS mutation RMC-6236 targeted therapy

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC